Pergolide |
![]() Last updated: 15/09/2025 |
![]() |
(Not known by any other names) |
|
![]() |
|
A dopamine agonist veterinary medication for Equine Cushing's Disease | |
---|---|---|
|
Pituitary pars intermedia dysfunction (PPID), also known as equine Cushing's syndrome | |
|
Horses |
Approval status |
|
Approved - usually supplied as a prescription only medicine to be authorised by a veterinarian (POM-V) | |
---|---|---|
|
Approved |
Chemical structure |
|
Pergolide exhibits optical isomerism, due to the presence of multiple chiral centres in its ergoline-based structure. The molecule has three defined stereocentres at positions 6a, 9, and 10a, which give rise to distinct enantiomers or diastereomers depending on their spatial configuration. In clinical and veterinary practice, pergolide is used as a single stereoisomer. | |
---|---|---|
|
C₁₉H₂₆N₂S | |
|
CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC | |
|
- | |
|
YEHCICAEULNIGD-MZMPZRCHSA-N | |
|
InChI=1S/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s1 | |
|
Yes |
General status |
|
- | |
---|---|---|
|
Diamine drug | |
|
- | |
|
- | |
|
Synthetic | |
|
Acts as a dopamine receptor agonis | |
|
[Dopamine D2 receptor, Agonist], [Dopamine D3 receptor, Agonist], [Dopamine D4 receptor, Agonist], [Dopamine D1B receptor, Agonist], [[Dopamine D1A receptor, Agonist], [5-hydroxytryptamine receptor 1A, Agonist], [5-hydroxytryptamine receptor 2B, Agonist], [5-hydroxytryptamine receptor 2A, Agonist] | |
|
66104-22-1 | |
|
811-107-4 | |
|
- | |
|
- | |
|
47811 | |
|
Nervous system: Dopamine agonist | |
|
QN04BC02. | |
|
No | |
|
- | |
|
314.49 | |
|
- | |
|
(6aR,9R,10aR)-9-(methylsulfanylmethyl)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline | |
|
- | |
|
- | |
|
- | |
|
- | |
|
- |
Commercial |
|
|
|||
---|---|---|---|---|
|
Current | |||
|
1982, first clinical approvals; 2007, withdrawn USA & Canada | |||
|
|
|||
|
|
|||
|
Usually formulated using pergolide mesilate in tablet form | |||
|
The production of pergolide begins with 9,10-dihydrolysergic acid, which is derived from lysergic acid, a natural compound obtained via fermentation of Claviceps purpurea. The synthesis involves selective functionalisation of the ergoline ring system, including N-propylation at the 6-position and the introduction of a methylthiomethyl group at the 8beta-position. These transformations are carried out under controlled conditions using reagents like alkyl halides and thiol derivatives, often in polar aprotic solvents such as N-methylpyrrolidone. Modern methods favour one-pot reactions that avoid isolating unstable intermediates, improving both yield and safety. | |||
|
As microbial-based products tend to use fermentation-based production processes rather than chemical synthesis, they typically have a lower fossil fuel input in formulation and active ingredient creation, and also have reduced downstream emissions due to biodegradability and minimal soil disruption, their life-cycle GHG emissions are expected to be low. Whilst hard and precise data is not available, broad estimates suggest that typically emissions are likely to be below 5 kg CO₂e/kg. |
|
![]() |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
- | |||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- |
Degradation |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
As this parameter is not normally measured directly, a surrogate measure is used: ‘Photochemical oxidative DT₅₀’. Where data is available, this can be found in the Fate Indices section below. | ||||||||||
|
- |
Soil adsorption and mobility |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
|
- |
Fate indices |
|
|
|
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||||||||||||||||||||
|
|
- | - | - | |||||||||||||||||||||||||
|
- | - |
Known metabolites |
None
|
![]() |
Terrestrial ecotoxicology |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
54.0 | E4 E = Manufacturers safety data sheets Mouse4 = Verified data |
High | ||||||||
|
|
- | - | - | |||||||
|
- | - | |||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
- | |||||||||||
|
- | - | - | ||||||||
- | |||||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - |
Aquatic ecotoxicology |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - |
|
- | - | - | |||
|
- | - | - |
|
![]() |
General |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
54.0 | E4 E = Manufacturers safety data sheets Mouse4 = Verified data |
High | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
Intraperitoneaal LD₅₀ = 6.3 mg kg⁻¹ | E4 E = Manufacturers safety data sheets Rat4 = Verified data |
- | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | |||||||||
|
- | ||||||||||
|
Rapidly eliminated with excretion via the kidney | Q3 Q = Miscellaneous data from online sources 3 = Unverified data of known source |
- |
Health issues |
|
|
||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Possible cardio toxin - may cause cardiac valve dysfunction May cause hypotension, nausea, and vomiting |
Handling issues |
|
|
|||
---|---|---|---|---|
|
No information available | |||
|
Health: H300 | |||
|
- | |||
|
UN2811 | |||
|
Packaging group II (moderate danger) | |||
|
Shelf life of the veterinary medicinal product as packaged for sale: 3 years. Store under cool conditions |
|
![]() |
|
|
||
---|---|---|---|
|
pergolide | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- |
Record last updated: | 15/09/2025 |
Contact: | aeru@herts.ac.uk |
Please cite as: | Lewis, K.A., Tzilivakis, J., Warner, D. and Green, A. (2016) An international database for pesticide risk assessments and management. Human and Ecological Risk Assessment: An International Journal, 22(4), 1050-1064. DOI: 10.1080/10807039.2015.1133242 |